The company's application requests approval for patients with lymphatic cancer who have stopped responding to Rituxin, a treatment for arthritis and cancer made by Genentech Inc. and Biogen Idec Inc..

Cephalon submitted three studies to FDA that showed Treanda had a positive response in lymphatic cancer patients and side effects similar to other chemotherapy drugs.

Roughly 30,000 people in the U.S. are diagnosed with lymphatic cancer each year.

In September Cephalon submitted another application to FDA for Treanda as a treatment for chronic lymphocytic leukemia, a slowly progressing blood and bone marrow disorder. FDA is still reviewing the application.

Shares of Cephalon Inc. fell 64 cents Monday to close at $71.76.